Home » Stocks » Cumberland Pharmaceuticals

Cumberland Pharmaceuticals, Inc. (CPIX)

Stock Price: $3.42 USD 0.04 (1.18%)
Updated Aug 12, 2020 2:05 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 51.85M
Revenue (ttm) 47.13M
Net Income (ttm) -4.52M
Shares Out 15.16M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $3.42
Previous Close $3.38
Change ($) 0.04
Change (%) 1.18%
Day's Open 3.59
Day's Range 3.39 - 3.59
Day's Volume 41,238
52-Week Range 3.10 - 6.10

More Stats

Market Cap 51.85M
Enterprise Value 46.10M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 15.16M
Float 7.80M
EPS (basic) -0.3
EPS (diluted) -0.30
FCF / Share 0.21
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 6.04%
Payout Ratio n/a
Shares Short 80,732
Short Ratio 5.80
Short % of Float 1.02%
Beta 0.42
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 16.56
PS Ratio 1.10
PB Ratio 1.03
Revenue 47.13M
Operating Income -5.29M
Net Income -4.52M
Free Cash Flow 3.13M
Net Cash 5.75M
Net Cash / Share 0.38
Gross Margin 82.28%
Operating Margin -11.23%
Profit Margin -10.30%
FCF Margin 6.64%
ROA -2.44%
ROE -8.08%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$9.75*
Low
9.75
Current: $3.42
High
9.75
Target: 9.75
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue47.5340.7441.1533.0333.5236.9032.0348.8551.1445.88
Revenue Growth16.67%-0.99%24.6%-1.47%-9.17%15.22%-34.44%-4.48%11.48%-
Gross Profit38.7833.3633.7827.0728.5531.8526.5943.8145.7842.29
Operating Income-3.62-7.39-4.08-1.431.113.56-3.808.829.856.50
Net Income-3.54-6.96-7.98-0.940.732.42-2.105.845.662.46
Shares Outstanding15.4015.6115.9116.2416.7217.6218.3319.5620.3420.33
Earnings Per Share-0.23-0.45-0.50-0.060.040.14-0.110.300.280.12
EPS Growth-----71.43%--7.14%133.33%-
Operating Cash Flow3.063.11-0.560.575.886.690.757.148.720.35
Capital Expenditures-1.02-4.28-1.49-2.13-2.70-3.26-7.56-2.54-0.44-0.77
Free Cash Flow2.04-1.16-2.05-1.563.183.43-6.814.608.28-0.42
Cash & Equivalents28.2136.2350.0950.1352.7754.7154.8971.0470.6065.89
Total Debt21.5020.009.804.101.70--4.364.867.78
Net Cash / Debt6.7216.2340.2946.0351.0754.7154.8966.6865.7458.12
Assets10511393.2393.4091.9295.4187.6198.5995.5292.05
Liabilities53.4657.1229.3120.2815.1014.658.3213.0312.6814.34
Book Value51.1255.8464.1273.2576.8980.7679.4785.7082.9377.78
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Cumberland Pharmaceuticals, Inc.
Country United States
Employees 94
CEO A. J. Kazimi

Stock Information

Ticker Symbol CPIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - Other
Unique Identifier NASDAQ: CPIX
IPO Date August 11, 2009

Description

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology markets in the United States and internationally. It offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol injection for treating hyponatremia; Ethyol injection for the reduction of xerostomia; Totect injection, for emergency oncology intervention, to treat the toxic effects of anthracycline chemotherapy; and Vibativ injection, for the treatment of certain serious bacterial infections. The company's Phase II product candidates includes Hepatoren injection for the treatment of critically ill patients suffering from liver and kidney failure; Boxaban oral capsules for the treatment of asthma patients; Vasculan oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as severe disabling psoriasis. The company markets and sells its products through sales representatives and district managers. Cumberland Pharmaceuticals Inc. has a strategic alliance with Clinigen Group plc and Nordic Group B.V. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.